BiotechTube
Inthera Bioscience

Inthera Bioscience

Zurich, Switzerland· Est.
intherabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $75M

Overview

Inthera Bioscience is a private, preclinical-stage biotech developing a novel oncology therapeutic platform. Its lead asset, INTH-454, is a first-in-class small molecule inhibitor of the NELF transcription complex, designed to selectively kill highly proliferative tumor cells by exacerbating their inherent replication stress. The company is IND-ready, with an initial clinical focus on advanced prostate cancer (CRPC) and colorectal cancer (CRC), and is backed by a management team with extensive industry experience and Aglaia Oncology Funds as a key shareholder.

Oncology

Technology Platform

Platform focused on small molecule inhibitors of the Negative Elongation Factor (NELF) complex, a transcriptional regulator, to induce lethal replication stress selectively in cancer cells.

Funding History

2
Total raised:$75M
Series B$50M
Series A$25M

Opportunities

INTH-454 addresses large oncology markets (CRPC, CRC) with high unmet need, offering a first-in-class mechanism that could be effective in multiple tumor types with high replication stress.
Successful clinical proof-of-concept could attract partnership deals or acquisition interest from larger pharma companies seeking novel oncology assets.

Risk Factors

High binary risk as a single-asset company with a novel, unproven mechanism in humans.
Requires significant additional capital to fund clinical trials.
Faces intense competition in the oncology space from other targeted therapies and replication stress pathway inhibitors.

Competitive Landscape

Inthera competes in the crowded oncology therapeutics space but differentiates itself via a first-in-class mechanism targeting the NELF transcription complex. Its primary competitors are other companies targeting replication stress pathways (e.g., ATR, CHK1, WEE1 inhibitors) and developers of novel therapies for CRPC and CRC. Its success hinges on demonstrating a superior or differentiated clinical profile.

More companies in Small Molecule Drugs →More companies in Switzerland →